AbbVie has entered a patent license agreement with Mylan regarding its proposed biosimilar adalimumab product, according to a press release.
Under the agreement, Mylan will get a nonexclusive license to AbbVie’s intellectual property related to Humira in the United States and other countries, excluding Europe, beginning July 31, 2023, and will pay royalties to AbbVie for licensing its Humira patents once the biosimilar product is launched. AbbVie will not make any payments to Mylan under the terms of the agreement.
Humira is approved by the FDA for 10 indications, including (Read more...)
Uncategorized